6946-15-2 Usage
Uses
Used in Pharmaceutical Industry:
3-Hydroxy-4-methyl-2-nitrobenzoic acid is utilized as an antimicrobial agent in the pharmaceutical industry, leveraging its ability to inhibit the growth of various microorganisms, thereby contributing to the development of treatments for infectious diseases.
Used in Organic Synthesis:
3-HYDROXY-4-METHYL-2-NITROBENZOIC ACID serves as a building block in the synthesis of a range of organic compounds, facilitating the creation of new chemical entities with diverse applications in various industries, including pharmaceuticals, agrochemicals, and materials science.
Used in Material Science:
3-Hydroxy-4-methyl-2-nitrobenzoic acid has been studied for its potential in the development of novel materials, where its unique structure and properties could be harnessed to create innovative materials with specific characteristics for specialized applications.
Used as a Fluorescent Probe:
In the field of sensing and imaging, 3-Hydroxy-4-methyl-2-nitrobenzoic acid is explored as a fluorescent probe, capitalizing on its optical properties to detect and visualize specific targets or changes in the environment, which is valuable in research and diagnostic applications.
Check Digit Verification of cas no
The CAS Registry Mumber 6946-15-2 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 6,9,4 and 6 respectively; the second part has 2 digits, 1 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 6946-15:
(6*6)+(5*9)+(4*4)+(3*6)+(2*1)+(1*5)=122
122 % 10 = 2
So 6946-15-2 is a valid CAS Registry Number.
InChI:InChI=1/C8H7NO5/c1-4-2-3-5(8(11)12)6(7(4)10)9(13)14/h2-3,10H,1H3,(H,11,12)
6946-15-2Relevant academic research and scientific papers
SUBSTITUTED 2-AMINO-FUSED HETEROCYCLIC COMPOUNDS
-
Page/Page column 27; 87, (2008/06/13)
The present invention relates to compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein: R1, R2, Z1, t, and ring A are as defined in the specification. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and methods of treating a condition that is mediated by the modulation of JNK, such as diabetes, the method comprising administering to a mammal an effective amount of a compound of formula (I).
